

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Axel RIEDEL et al.) Art Unit: 1614
Serial No.: 10/757,015) Examiner: Leslie A. ROYDS
Confirmation No.: 3296
Filed: January 14, 2004
For: PHARMACEUTICAL COMBINATION FOR THE PREVENTION OR
 TREATMENT OF CARDIOVASCULAR, CARDIOPULMONARY,
 PULMONARY OR RENAL DISEASES
Docket No.: 01-1443

Via EFS Web
Commissioner for Patents
Alexandria, VA 22313-1450

PETITION UNDER 37 CFR 1.136(a) FOR EXTENSION OF TIME

Sir:

It is hereby requested that the time for responding to the Action mailed on October 14, 2010 be extended pursuant to 37 CFR 1.136(a) for three (3) months, so that the extended period for response will end on April 14, 2011. Applicants intend to file a continuation application, claiming priority to this application, during this time period.

The fee set in 37 CFR 1.17 for this extension of time is \$1,100.00 and will be paid during electronic filing via the Revenue Accounting and Management System. However, if it is determined that any additional fees under 37 C.F.R. §§ 1.16 and 1.17 are due in connection with this Reply, the Director is hereby authorized to charge such fees, and/or to credit any overpayment, to Deposit Account No. 02-2955.

Respectfully submitted,

/Timothy X. Witkowski /
Timothy X. Witkowski
Attorney for Applicant(s)
Reg. No. 40,232

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT. 06877
Tel.: (203) 798-4310
Fax: (203) 798-4408

Date: April 13, 2011